エピソード

  • Fellow Eye RRD Risk per IRIS Registry

    Fellow Eye RRD Risk per IRIS Registry
    2025/05/07
    Questions abound about fellow eye rhegmatogenous retinal detachments (RRD). How often do fellow eye develop RRD after the first one is repaired? What concomitant conditions do fellow eyes with RRD have? What risk factors exist for fellow eye RRD? And which procedures are used to repair fellow eye RRD? Moderator Barton Blackorby, MD, and panelists Louis Cai, MD, and Hong-Uyen Hua, MD, dissect the latest data on these questions from the AAO IRIS Registry and then compare how these data align with their respective clinical experiences.
    続きを読む 一部表示
    17 分
  • Rates of Ocular AEs After Faricimab Injection

    Rates of Ocular AEs After Faricimab Injection
    2025/03/21
    What are the real-world safety data following administration of faricimab (Vabysmo, Genentech)? Maura Di Nicola, MD, and guests Sruthi Arepalli, MD, and Barton Blackorby, MD, review data from a real-world, single-center, retrospective study of approximately 4500 injections of faricimab in over 700 patients at Wills Eye Hospital. What did the data show? And do these data effect the clinical patterns of Drs. Di Nicola, Arepalli, and Blackorby?
    続きを読む 一部表示
    18 分
  • Treating Geographic Atrophy (GA) In Your Practice

    Treating Geographic Atrophy (GA) In Your Practice
    2025/03/05
    Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.
    続きを読む 一部表示
    19 分
  • Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy

    Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy
    2025/03/05
    Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.
    続きを読む 一部表示
    22 分
  • Using OCT Angiography to Distinguish RVO and RAO

    Using OCT Angiography to Distinguish RVO and RAO
    2025/01/09
    How can OCT angiography help retina specialists distinguish between retinal vein occlusion (RVO) and retinal artery occlusion (RAO) in patients who present without acute findings? Using real-world cases as a backdrop, Yasha Modi, MD, and Kat Talcott, MD, discuss Dr. Modi’s approach to distinguishing RVO and RAO via OCT angiography and review which specific OCT angiography findings may indicate referral to cardiology. Later in the episode, they explore the utility and limitations of OCT angiography in patients with diabetic retinopathy. This episode is supported by Zeiss Professional Education.
    続きを読む 一部表示
    18 分
  • OCT Angiography in a Real-world CSR Case

    OCT Angiography in a Real-world CSR Case
    2025/01/09
    What role can OCT angiography play in tracking the development of central serous retinopathy (CSR)? Yasha Modi, MD, and Kat Talcott, MD, review the use of OCT angiography in a real-world CSR case, discuss the value of selecting OCT angiography over fluorescein angiography for patients with neovascularization, and parse which populations are not a good fit for OCT angiography. This episode is supported by Zeiss Professional Education.
    続きを読む 一部表示
    18 分
  • Switching from Aflibercept to Faricimab in Wet AMD Patients

    Switching from Aflibercept to Faricimab in Wet AMD Patients
    2024/12/19
    Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And are significant improvements in anatomy relevant if vision gains are unchanged?
    続きを読む 一部表示
    22 分
  • GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?

    GA Options in Clinical Therapy: Which Patients Are a Fit for GA Treatment?
    2024/12/12
    What are the benefits and limitations to FDA-approved therapies for geographic atrophy? John Kitchens, MD, is joined by Saradha Chexal, MD, and Geeta Lalwani, MD, as they explore which patients are best suited for treatment, how best to succinctly set expectations for outcomes, and whether patients on GA therapy may also be well-suited AREDS vitamins.
    続きを読む 一部表示
    17 分